Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Global Mammalian Polyclonal IgG Antibody Market Analysis Report 2018 Featuring Abcam, Bio-Rad Labs, Thermo Fisher Scientific, Merck, Cell Signaling Technologies Hoffmann-La Roche


DUBLIN, Nov. 16, 2018 /PRNewswire/ --

The "Mammalian Polyclonal IgG Antibody Market Size, Share & Trends Analysis Report By Type (Mouse, Rabbit), By Product (Cardiac, Metabolic), By Application, By End Use, By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.21 billion by 2025 expanding at a CAGR of 5.1%.

Advantages over other forms of antibodies, increasing global R&D investments, and rising adoption of novel diagnostic procedures are factors driving the market. Global rise in chronic and infectious diseases also play a key role in propelling the market growth.

Polyclonal antibodies are the most preferred choice in routine laboratory tests, such as ELISA, microarray assays, western blotting, flow cytometry, and immunohistochemistry. Production of these does not require skilled professionals and large batches can be produced as per client requirements. A polyclonal antibody can recognize multiple antigens on one epitope and therefore can be utilized in the study of various diseases ranging from cancer to metabolic diseases. Denatured proteins are often detected with the use of polyclonal antibodies.

Thus, increasing use of these products in the treatment of several chronic diseases is also anticipated to fuel growth in the near future. Rising investments by major pharma companies, such as Novartis and Roche, for the development of therapeutic antibodies and novel diagnostic techniques and for QC purposes are also driving the market growth.

For instance, R&D investments by top 10 biotech companies increased from USD 8.2 billion in 2010 to USD 10.2 billion in 2016, accounting for a 13% increase.

Further key findings from the study suggest:

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Mammalian Polyclonal IgG Antibody Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Advantages Over Monoclonal Antibodies
3.1.1.2 Rising R&D investments
3.1.1.3 Increasing Adoption of Novel Diagnostic Procedures
3.1.2 Market Resraint Analysis
3.1.2.1 Stringent Regulatory Policies
3.1.3 Key Opportunities Prioritized
3.1.3.1 Key Opportunities Prioritized, by type
3.1.3.2 Key Opportunities Prioritized, by product
3.1.3.3 Key Opportunities Prioritized, by Application
3.1.3.4 Key Opportunities Prioritized, by End Use
3.1.4 Mammalian IgG Polyclonal Antibody - SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.1.5 Industry Analysis - Porter's
3.1.6 Mammalian IgG Polyclonal Antibody Market: Company Market Position Analysis, 2017

Chapter 4 Mammalian Polyclonal IgG Antibody Market: Type Analysis
4.1 Type Business Analysis
4.2 Mammalian IgG Polyclonal Antibody Market: Type Movement Analysis
4.2.1 Goat
4.2.2 Rabbit
4.2.3 Horse
4.2.4 Mouse
4.2.5 Others

Chapter 5 Mammalian Polyclonal IgG Antibody Market: Product Analysis
5.1 Product Business Analysis
5.2 Cardiac Biomarkers
5.3 Metabolic Biomarkers
5.4 Renal Biomarkers
5.5 Others

Chapter 6 Mammalian Polyclonal IgG Antibody Market: Application Analysis
6.1 Application Business Analysis
6.1.1 ELISA
6.1.2 Immunoturbidimetry
6.1.3 Immunoelectrophoresis
6.1.4 Antibody Identification
6.1.5 Immunohistochemistry
6.1.6 Immunocytochemistry
6.1.7 Western Blotting

Chapter 7 Mammalian Polyclonal IgG Antibody Market: End Use Analysis
7.1 End Use Business Analysis
7.2 Hospitals
7.3 Diagnostic Centers
7.4 Academic and Research Centers

Chapter 8 Mammalian Polyclonal IgG Antibody Market: Regional Estimates & Trend Analysis, by Type, Product, Application, End-Use

Chapter 9 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/j4zdhn/global_mammalian?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...

at 17:00
L.A. Care Health Plan and Blue Shield of California Promise Health Plan today held a grand opening ceremony for their Community Resource Center (CRC) in West Los Angeles (West L.A.) at 11173 W. Pico Blvd in Los Angeles....

at 16:55
Veterinary Management Groups (VMG) is proud to...

at 16:45
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered...



News published on and distributed by: